Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

KPTI Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Karyopharm Therapeutics Inc.NASDAQ: KPTI

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense declines year over year

Q1 FY2026 income tax expense of $1K fell 97.2% year over year, behind the -63.6% change in trailing-twelve-month income tax expense. Over 3 fiscal years it compounded at -51.2% a year.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -97.2% toward the trailing-twelve-month pace of -63.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1K+101.5% QoQ
Last fiscal yearDec 2025
$43K-24.6% YoY
LTMMar 2026
$8K-63.6% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.2%——
1 year-24.6%——
3-year CAGR-51.2%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
43K USD
Year-over-year change
-24.6%
4-year CAGR
-36.7%

Income Tax Expense vs competitors

How KPTI compares with its peers on the latest reported figures

  • KPTI's LTM Mar 2026 income tax expense of $8K is the highest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of -63.6% is the highest of 2, against a peer median of -97.8%.
  • Income tax expense amounts to 0.0% of revenue for KPTI, versus a peer median of 0.1%.
KPTI Competitors Peer median
Income Tax Expense for KPTI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$8K -63.6%-51.2%0.0%
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$7K -97.8%+13.6%0.1%
INMBINmune Bio, Inc.LTM Mar 2026$0 ———
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding KPTI) $0-97.8%+13.6%0.1%

Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue209.82M157.07M146.03M145.24M146.07M
Cost of Revenue3.4M5.21M4.94M6.01M5.95M
Gross Profit206.42M151.86M141.09M139.23M140.12M
Gross Margin98.4%96.7%96.6%95.9%95.9%
Research & Development160.84M148.66M138.75M143.23M125.62M
Selling, General & Admin143.85M145.4M131.88M115.44M105.21M
Operating Expenses304.69M294.06M270.63M258.67M230.83M
Depreciation & Amortization789K621K530K340K296K
EBITDA(96.99M)(139.31M)(118.42M)(38.6M)(149.85M)
EBITDA Margin-46.2%-88.7%-81.1%-26.6%-102.6%
Operating Income(98.27M)(142.2M)(129.54M)(119.44M)(90.71M)
Operating Margin-46.8%-90.5%-88.7%-82.2%-62.1%
Interest Income582K2.36M10.94M7.4M2.77M
Interest Expense26.05M25M23.82M37.42M45.85M
Other Income / Expenses(25.55M)(22.72M)(13.24M)43.08M(105.29M)
Income Before Tax(123.82M)(164.92M)(142.78M)(76.37M)(196M)
Pre-Tax Margin-59.0%-105.0%-97.8%-52.6%-134.2%
Income Tax Expense268K369K323K57K43K
Net Income(124.09M)(165.29M)(143.1M)(76.42M)(196.04M)
Net Margin-59.1%-105.2%-98.0%-52.6%-134.2%
EPS (Basic)(24.75)(30.28)(18.79)(9.41)(17.93)
EPS (Diluted)(24.75)(30.28)(18.79)(9.41)(17.93)
Weighted Avg Shares5.01M5.46M7.61M8.12M10.94M
Weighted Avg Shares (Diluted)5.01M5.46M7.61M8.12M10.94M

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Intrinsic Alpha fair value

Locked

Current Price

$7.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.